ArticleCytometry. Part B, Clinical cytometry2016
Assessment of minimal residual disease in myeloma and the need for a consensus approach.
Article in Cytometry. Part B, Clinical cytometry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.The New England journal of medicine · 2017Trial
- An Update on Flow Cytometry Analysis of Hematological Malignancies: Focus on Standardization.Cancers · 2025Review
- The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma.Discover oncology · 2024Review
- POEMS syndrome with undetectable M-protein: a case report and literature review.Diagnostic pathology · 2024Review
- Review
- Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.Cytometry. Part B, Clinical cytometry · 2022Article
- "Friends and foes" of multiple myeloma measurable/minimal residual disease evaluation by next generation flow.Frontiers in oncology · 2022Review
- Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium.Diagnostics (Basel, Switzerland) · 2021Article
- Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.Cytometry. Part B, Clinical cytometry · 2020Article
- Monitoring minimal residual disease in the bone marrow using next generation sequencing.Best practice & research. Clinical haematology · 2020Review
- Article
- [Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma.Scientific reports · 2019Article
- Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.Frontiers in oncology · 2019Review
- Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.Bone marrow transplantation · 2018Article
- Minimal residual disease analysis in myeloma - when, why and where.Leukemia & lymphoma · 2018Review
- Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Clinics in laboratory medicine · 2017Review
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.Leukemia · 2017Article
- MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods.Blood advances · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Treatment options for myeloma continue to develop at a rapid pace, and it is becoming increasingly challenging to determine the optimal therapeutic approaches because demonstrating a clear survival benefit now requires many years of follow-up. The detection of minimal residual disease (MRD) is recognized as a sensitive and rapid approach to evaluate treatment efficacy that predicts progression-free and overall survival independent of categorical response assessment and patients' biology. The benefit of MRD analysis is reflected in the many different techniques (multiparameter flow cytometry, quantitative polymerase chain reaction, and high-throughput sequencing) and collaborative groups (including EMN, ESCCA, ICCS, EuroFlow, and EuroMRD) that have performed collaborative projects to harmonize quantitative MRD detection. The time has come to adopt a consensus approach, and this report reviews the benefits and disadvantages of different strategies for MRD detection in myeloma and highlights the requirements for a sensitive, reproducible, and clinically meaningful cellular analytical approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.